Insulin receptor
20 drugs Metabolic
3
approved indications
20
Approved Drugs
7
Companies
4
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (7 companies)
✓ All 20 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (4 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novo Nordisk 8 drugs
Eli Lilly 5 drugs
SANOFI-AVENTIS US 2 drugs
By Therapeutic Area
Metabolic 20 drugs
Drugs by Company PRO
Novo Nordisk 8 drugs
Eli Lilly 5 drugs
SANOFI-AVENTIS US 2 drugs
SANOFI-AVENTIS U.S. LLC 2 drugs
Viatris 1 drug
Baxter 1 drug
Sanofi 1 drug
By Therapeutic Area
Metabolic 20 drugs
BASAGLAR, REZVOGLAR, SEMGLEE, XULTOPHY 100/3.6 +16 more
Indications Treated
DiabetesDiabetic KetoacidosisType 1 DiabetesType 2 Diabetes
All Drugs Targeting Insulin receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| BASAGLAR | Eli Lilly | 2015 | 3 | Metabolic |
| REZVOGLAR | Eli Lilly | 2021 | 2 | Metabolic |
| SEMGLEE | Viatris | 2020 | 2 | Metabolic |
| XULTOPHY 100/3.6 | Novo Nordisk | 2016 | 2 | Metabolic |
| SOLIQUA 100/33 | SANOFI-AVENTIS US | 2016 | 2 | Metabolic |
| ADLYXIN | SANOFI-AVENTIS US | 2016 | 2 | Metabolic |
| LYUMJEV | Eli Lilly | 2020 | 1 | Metabolic |
| FIASP PENFILL | Novo Nordisk | 2017 | 1 | Metabolic |
| FIASP | Novo Nordisk | 2017 | 1 | Metabolic |
| FIASP FLEXTOUCH | Novo Nordisk | 2017 | 1 | Metabolic |
| HUMALOG KWIKPEN | Eli Lilly | 1996 | 1 | Metabolic |
| MERILOG | SANOFI-AVENTIS U.S. LLC | 2025 | 1 | Metabolic |
| MERILOG SOLOSTAR | SANOFI-AVENTIS U.S. LLC | 2025 | 1 | Metabolic |
| NOVOLOG MIX 70/30 | Novo Nordisk | 2001 | 1 | Metabolic |
| TRESIBA | Novo Nordisk | 2015 | 1 | Metabolic |
| NOVOLOG | Novo Nordisk | 2000 | 1 | Metabolic |
| HUMALOG | Eli Lilly | 1996 | 1 | Metabolic |
| LEVEMIR | Novo Nordisk | 2005 | 1 | Metabolic |
| MYXREDLIN | Baxter | 2019 | 1 | Metabolic |
| LANTUS | Sanofi | 2000 | 1 | Metabolic |